|1.||Psoriasis (Pustulosis Palmaris et Plantaris)
|5.||Crohn Disease (Crohn's Disease)
|1.||Gladman, Dafna D: 54 articles (11/2015 - 10/2005)|
|2.||Mease, Philip J: 45 articles (11/2015 - 04/2002)|
|3.||Kavanaugh, Arthur: 38 articles (10/2015 - 04/2005)|
|4.||Chandran, Vinod: 28 articles (10/2015 - 03/2008)|
|5.||Scarpa, Raffaele: 25 articles (11/2015 - 07/2006)|
|6.||Ritchlin, Christopher T: 23 articles (11/2015 - 02/2003)|
|7.||Krueger, Gerald G: 21 articles (09/2014 - 04/2002)|
|8.||Rahman, Proton: 20 articles (10/2015 - 10/2004)|
|9.||Gottlieb, Alice B: 20 articles (09/2015 - 09/2003)|
|10.||FitzGerald, Oliver: 19 articles (01/2016 - 06/2003)|
|1.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
07/01/2014 - "Anti-tumor necrosis factor medications have demonstrated good efficacy in treating psoriatic arthritis (PsA). "
05/01/2008 - "All 3 TNF-alpha inhibitors were significantly more effective than placebo on the basis of Psoriatic Arthritis Response Criteria (PsARC) and American College of Rheumatology response criteria ACR20, ACR50, and ACR70 ratings. "
12/01/2002 - "After the efficacy of anti-TNFalpha therapy in AS and psoriatic arthritis is proved, respondents agreed that more studies will be needed to show efficacy for other SpA subsets."
07/01/2013 - "Recently, it has been demonstrated that tumor necrosis factor alpha (TNF-alpha) plays a pivotal role in inducing and maintaining joint damage and that molecules that block this cytokine are effective in the treatment of psoriatic arthritis. "
05/01/2009 - "Tumor necrosis factor inhibitors are an effective treatment for psoriatic arthritis, but no single agent is effective in all patients. "
|2.||TNFR-Fc fusion protein (etanercept)FDA Link
01/01/2003 - "In the 24-week study, ACR20 response rates (50 vs 13%), psoriatic arthritis response rates (70 vs 23%) and the median improvement in skin lesions (33 vs 0%) were significantly greater in etanercept than in placebo recipients. "
01/01/2003 - "In patients with psoriatic arthritis, etanercept 25mg twice weekly significantly reduced disease activity and improved skin lesions in two double-blind, placebo-controlled, 12- to 24-week trials. "
01/01/2002 - "In the 24-week study, ACR20 response rates (50 vs 13%), psoriatic arthritis response rates (70 vs 23%) and the median improvement in skin lesions (33 vs 0%) were significantly greater in etanercept than in placebo recipients. "
01/01/2002 - "In patients with psoriatic arthritis, etanercept 25mg twice weekly significantly reduced disease activity and improved skin lesions in two double-blind, placebo-controlled, 12- to 24-week trials. "
11/01/2000 - "In patients with severe psoriatic arthritis (PsA), a double blind, placebo controlled study demonstrated that etanercept was also effective in reducing disease activity in PsA. "
|3.||infliximab (Remicade)FDA Link
01/01/2011 - "Despite its proven efficacy, infliximab is often considered to be an expensive treatment for patients with psoriatic arthritis. "
08/01/2006 - "Infliximab is effective in improving signs and symptoms of joint/skin involvement, functional status, and quality of life in patients with psoriatic arthritis (PsA). "
08/01/2005 - "To evaluate further in a phase III, double blind trial the efficacy of infliximab in patients with active psoriatic arthritis (PsA), as observed in the smaller IMPACT trial. "
06/01/2007 - "Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis."
08/15/2003 - "Efficacy of infliximab in resistant psoriatic arthritis."
|4.||adalimumab (Humira)FDA Link
11/01/2009 - "Radiologically significant joint improvement in a patient affected by psoriatic arthritis treated with adalimumab."
01/01/2012 - "Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study."
11/01/2009 - "We describe a psoriatic arthritis patient whose lymphoedema greatly improved following commencement of adalimumab."
01/01/2015 - "Association between skin and joint involvement in patients with psoriatic arthritis treated with adalimumab: analysis of data from a German non-interventional study."
09/01/2010 - "Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study."
|5.||Methotrexate (Mexate)FDA LinkGeneric
11/01/1994 - "Methotrexate can be used early in the course of psoriatic arthritis with good results."
05/01/2012 - "Spondyloarthritis: Is methotrexate effective in psoriatic arthritis?"
12/01/1995 - "Is methotrexate really effective in patients with psoriatic arthritis?"
05/01/2014 - "Methotrexate (MTX) has become the first-line treatment for rheumatoid (RA) and psoriatic arthritis (PsA); however, few studies have focused on its tolerability. "
04/01/2013 - "Comment on: A randomized placebo-controlled trial of methotrexate in psoriatic arthritis: reply."
|6.||monoclonal antibody CNTO 1275 (CNTO 1275)FDA Link
08/31/2013 - "Ustekinumab significantly improved active psoriatic arthritis compared with placebo, and might offer an alternative therapeutic mechanism of action to approved biological treatments. "
08/31/2013 - "We did a randomised, placebo-controlled, phase 3 trial to assess the safety and efficacy of ustekinumab in patients with active psoriatic arthritis. "
01/01/2013 - "Ustekinumab also improved joint symptoms of psoriatic arthritis. "
04/01/2011 - "A recent clinical trial also indicates the possible efficacy of ustekinumab in psoriatic arthritis. "
08/01/2009 - "The efficacy of ustekinumab on the articular and dermatologic manifestations of psoriatic arthritis."
|7.||Cyclosporine (Ciclosporin)FDA LinkGeneric
01/01/2000 - "An open 18-week study with a preparation of cyclosporin administered to patients with psoriatic arthritis confirmed the therapeutic efficacy of the preparation. "
01/01/1993 - "Therapeutic efficacy of oral low-dose cyclosporin A in severe psoriatic arthritis."
08/01/1990 - "Eight patients with psoriatic arthritis entered an open study to determine the efficacy of oral cyclosporin A for their treatment. "
04/01/1989 - "The short-term efficacy of cyclosporine in the treatment of six patients with moderately severe to severe psoriatic arthritis was evaluated in an open study. "
04/01/2002 - "Long-term safety and efficacy of low-dose cyclosporin A in severe psoriatic arthritis."
01/01/2009 - "In patients with psoriatic arthritis in the GO-REVEAL study, significantly more golimumab than placebo recipients achieved a >or=20% improvement in ACR criteria at week 14. "
08/01/2012 - "Golimumab, administered subcutaneously every 4 weeks, has been shown to be effective in reducing the signs and symptoms of active psoriatic arthritis (PsA) through week 24 of the GO-REVEAL study. "
01/01/2013 - "Clinical trials have demonstrated the efficacy of golimumab (GLB) in improving the signs and symptoms of psoriatic arthritis (PsA). "
09/01/2014 - "Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)."
05/01/2014 - "Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab."
|9.||Sulfasalazine (Azulfidine)FDA LinkGeneric
09/01/1991 - "Sulfasalazine appears to be an effective second line agent for the treatment of psoriatic arthritis. "
10/01/1998 - "Patients who were given sulfasalazine during their attendance at the University of Toronto Psoriatic Arthritis Clinic were enrolled in the study. "
07/01/1996 - "A prospective double-blind, placebo-controlled, randomized study of 24 weeks duration was carried out comparing the efficacy and tolerability of sulphasalazine (SSZ) versus placebo in patients with psoriatic arthritis. "
07/01/1996 - "Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study."
05/01/1995 - "Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial."
|10.||Antirheumatic Agents (DMARD)IBA
07/01/2012 - "Although several reviews and metaanalyses have shown lack of evidence of efficacy of traditional disease-modifying antirheumatic drugs (DMARD) in psoriatic arthritis (PsA), these drugs are very often used and are recommended by treatment guidelines around the world as first-line therapy for most patients with PsA. "
07/01/2004 - "A new crop of biologics and pharmaceuticals with increased molecular specificity compared with traditional immunosuppressant disease-modifying antirheumatic drugs have been shown to be highly effective in inhibiting the symptoms and progression of psoriatic arthritis with less severe side effects. "
11/01/2015 - "Traditional disease-modifying antirheumatic drugs (DMARD) remain the first-line treatment of psoriatic arthritis (PsA), despite lack of randomized controlled trials, and with evidence based on observational studies. "
11/01/2015 - "As for psoriatic arthritis (PsA), DMARD are widely used, but few trials are available about their effects on axial involvement, which is not often assessed as a primary outcome in clinical trials. "
05/01/2015 - "The primary objective of this study was to describe and compare clinical and musculoskeletal (MS) ultrasound (US) features between psoriatic arthritis (PsA) patients treated with full and tapered dosage of biologic (b) disease-modified antirheumatic drugs (DMARDs). "
07/01/2013 - "Remission in psoriatic arthritis (PsA), albeit variably defined, is a desirable and achievable state, especially in the era of biologic therapy. "
05/01/2012 - "The efficacy of antibody-based biological therapies currently used in psoriatic arthritis (PsA) depends not only on their blocking effect on the targeted molecule but also on their binding affinity to genetically defined variants of cell-surface Fc-γ receptors. "
10/15/2006 - "The aim of the study was to present the epidemiology and progression of psoriatic arthritis in Hungary based on national and international data, to assess the target population for biological therapy and to analyze their effectiveness, reviewing the available literature of randomized controlled trials. "
03/01/2005 - "Recent studies with biological therapy in psoriatic arthritis (PsA) have highlighted the need for validated and widely accepted assessment tools and outcome measures for this disease. "
12/01/2015 - "Patients with PsA classified by the ClASsification for Psoriatic ARthritis (CASPAR) criteria and consecutively admitted to an outpatient clinic dedicated to biologic therapy were assessed during their routine followup. "
01/01/2000 - "The purpose of this study was to evaluate the immediate and delayed effects of balneotherapy at the Dead Sea on patients with psoriatic arthritis (PsA). "
01/01/1984 - "[Balneotherapy and heliomarinotherapy in the treatment and rehabilitation of patients with psoriatic arthritis]."
02/01/2001 - "Balneotherapy at the Dead Sea area appears to produce a statistically significant substantial improvement in the number of active joints and tender points in both male and female patients with fibromyalgia and psoriatic arthritis. "
02/01/2001 - "Twenty-eight patients with psoriatic arthritis and fibromyalgia were treated with various modalities of balneotherapy at the Dead Sea area. "
02/01/2001 - "To assess the effectiveness of balneotherapy at the Dead Sea area in the treatment of patients suffering from both fibromyalgia and psoriatic arthritis. "
|3.||Drug Therapy (Chemotherapy)
10/01/2003 - "We reviewed MedLine up to November 2002, searching for 'psoriatic arthritis', 'drug therapy, 'controlled trials' and 'outcomes' and all possible acronyms for these terms. "
06/01/2015 - "[Pharmacotherapy of psoriatic arthritis. "
12/01/2013 - "Psoriatic arthritis: advances in pharmacotherapy based on molecular target."
03/01/2012 - "A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis."
08/01/2010 - "Psoriatic arthritis: pharmacotherapy update."
03/01/2015 - "New treatment paradigms in psoriatic arthritis: an update on new therapeutics approved by the U.S. "
07/01/2004 - "Therapeutics used to treat inflammatory diseases, including psoriatic arthritis (PsA), may potentially interfere with normal immune system function. "
06/01/2010 - "Our current understanding of the relationship between psoriasis and psoriatic arthritis remains incomplete, though the evidence from the clinical setting, response to therapeutics, epidemiology, genetics, imaging, and immunopathologic models suggest that they make likely share a common pathogenesis. "
03/01/2005 - "As a result of progress in immunology and biotechnology, several potent novel therapeutics have recently emerged for the treatment of patients with various immunologically driven systemic inflammatory conditions, including psoriasis and psoriatic arthritis. "
06/01/2013 - "The development of the differentiation of psoriatic arthritis from clinically similar symptoms, including relevant serologic and radiologic findings and therapeutics with a focus up to the 1960s and the recognition of the efficacy of methotrexate, is reported."
05/01/1999 - "A trial of dry air effervescent baths and low-temperature peloid applications was made in 109 patients with psoriatic arthritis (PA). "
01/01/1998 - "Low-temperature peloids and dry effervescent baths were tried in the treatment of 106 patients with psoriatic arthritis. "
11/01/1987 - "[Therapeutic efficacy of dry-air radon baths in the rehabilitation of patients with psoriatic arthritis]."
03/01/2003 - "[Efficacy of radon baths of different concentration in psoriatic arthritis]."
05/01/1999 - "[The effect of carbon dioxide baths and applications of low-temperature peloids on the immune function of patients with psoriatic arthritis]."